var data={"title":"Necrobiotic xanthogranuloma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Necrobiotic xanthogranuloma</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/contributors\" class=\"contributor contributor_credentials\">Courtney Schadt, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/contributors\" class=\"contributor contributor_credentials\">Eric Jacobsen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/contributors\" class=\"contributor contributor_credentials\">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 20, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1066258288\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Necrobiotic xanthogranuloma (NXG) is a form of non-Langerhans histiocytosis characterized by the development of red-brown, violaceous, or yellowish cutaneous papules and nodules that evolve to form infiltrated plaques. The periorbital skin is the most common site for NXG. Extracutaneous involvement of ocular, respiratory, cardiac, or other tissues may also occur in patients with NXG.</p><p>Most patients with NXG have an associated monoclonal gammopathy. Other hematologic disorders, including hematologic malignancies, also may occur in association with NXG.</p><p>The treatment of NXG is challenging and data on therapeutic options are limited, making the best approach to treatment unclear. Alkylating agents, such as <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a>, are commonly used treatments.</p><p>The clinical manifestations, diagnosis, and management of NXG will be reviewed here.</p><p class=\"headingAnchor\" id=\"H88245963\"><span class=\"h1\">HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In 1980, Kossard and Winkelmann described eight patients with multiple violaceous, atrophic plaques and nodules on the face (particularly periorbital area), skin flexures, and trunk with associated paraproteinemia [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/1,2\" class=\"abstract_t\">1,2</a>]. They named this condition necrobiotic xanthogranuloma based on the distinctive histologic finding of xanthogranulomas with zones of necrobiosis. (See <a href=\"#H192580489\" class=\"local\">'Histopathology'</a> below.)</p><p class=\"headingAnchor\" id=\"H1066258294\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NXG typically occurs in adults. The average age of onset is in the sixth decade with no gender predilection [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/3-6\" class=\"abstract_t\">3-6</a>].</p><p class=\"headingAnchor\" id=\"H1066258300\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of NXG is unclear. The association between NXG and paraproteinemias and the xanthomatous features of the disorder have contributed to several pathogenic theories:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NXG may represent a foreign-body giant cell reaction to the cutaneous and extracutaneous deposition of serum immunoglobulins complexed with lipids [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NXG may result from an accelerated complement reaction leading to activation of monocytes and accumulation of lipoprotein-derived lipids in monocytes [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NXG may be a result of impaired macrophage lipid homeostasis and an associated systemic inflammatory response. Patients with NXG may have a reduced capacity of high-density lipoprotein (HDL) to promote cholesterol efflux from macrophages leading to cholesterol accumulation [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/9\" class=\"abstract_t\">9</a>]. High plasma levels of proinflammatory cytokines, including interleukin-15, have been observed [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/9\" class=\"abstract_t\">9</a>].</p><p/><p class=\"headingAnchor\" id=\"H1066258306\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NXG may have both cutaneous and extracutaneous features.</p><p class=\"headingAnchor\" id=\"H1066258313\"><span class=\"h2\">Cutaneous</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The typical cutaneous features of NXG are yellow-orange, reddish-brown, or violaceous indurated papules and nodules that gradually enlarge to form infiltrative plaques (<a href=\"image.htm?imageKey=DERM%2F102781%7EDERM%2F102782\" class=\"graphic graphic_picture graphicRef102781 graphicRef102782 \">picture 1A-B</a>). The central aspect of larger plaques may become atrophic with prominent telangiectasia. The plaques are usually asymptomatic but are occasionally pruritic [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/10\" class=\"abstract_t\">10</a>]. Scarring and ulceration occur in 40 to 50 percent of patients (<a href=\"image.htm?imageKey=DERM%2F102783\" class=\"graphic graphic_picture graphicRef102783 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6\" class=\"abstract_t\">6</a>].</p><p>In most cases, more than one site is involved, including the trunk, face, arms, thighs, and lower legs [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4,11\" class=\"abstract_t\">4,11</a>]. The periorbital region is the most frequent site of involvement, occurring in approximately 70 to 80 percent of patients [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4,11\" class=\"abstract_t\">4,11</a>]. Periocular NXG often has a yellowish hue. In comparison to xanthelasmas, cholesterol-filled plaques that commonly occur on the eyelids, periocular NXG plaques are larger, more indurated, and more erythematous. Periorbital NXG may extend into the orbit, manifesting as soft tissue densities or diffuse orbital inflammation on computed tomography [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"#H356857559\" class=\"local\">'Ocular involvement'</a> below.)</p><p>Other reported presentations of NXG include ulcerated plaques on the extremities and trunk [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5,12,13\" class=\"abstract_t\">5,12,13</a>] or a solitary subcutaneous nodule or plaque [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/14-17\" class=\"abstract_t\">14-17</a>]. NXG has also been reported to occur on the genitalia [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/18\" class=\"abstract_t\">18</a>] and within preexisting scars [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/3,19-21\" class=\"abstract_t\">3,19-21</a>].</p><p class=\"headingAnchor\" id=\"H1066258319\"><span class=\"h2\">Extracutaneous</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extracutaneous involvement of NXG can occur in the eye (most common site) and other locations. In rare cases, extracutaneous NXG occurs in the absence of skin disease [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H356857559\"><span class=\"h3\">Ocular involvement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ocular involvement in NXG can mimic uveitis and scleritis, with conjunctival biopsy demonstrating necrobiotic xanthogranulomas [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/22,23\" class=\"abstract_t\">22,23</a>]. Approximately half of the 48 patients with NXG in a retrospective study had ophthalmic complaints, including pain, burning, itching, blurred vision, diplopia, acute transient vision loss, and dry eyes [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4\" class=\"abstract_t\">4</a>]. Patients can also develop proptosis and limited extraocular mobility from orbital involvement [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H356857632\"><span class=\"h3\">Other sites</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Involvement of internal organs or structures can occur in NXG. In a review of published reports of NXG, 18 percent of 130 patients were diagnosed with extracutaneous NXG affecting various sites, including pulmonary, cardiac, oral cavity, periorbital, hepatic, splenic, renal, and facial nerve tissues [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/11\" class=\"abstract_t\">11</a>]. The most common extracutaneous site is the respiratory tract; the second most common site is cardiac tissue [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/10\" class=\"abstract_t\">10</a>].</p><p>Additional reported sites for extracutaneous NXG include skeletal muscle, lacrimal glands, the frontal lobe, and bone marrow [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H1066258331\"><span class=\"h1\">ASSOCIATED DISORDERS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NXG occurs in association with monoclonal gammopathy in most but not all cases [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4,15,24\" class=\"abstract_t\">4,15,24</a>]. The overall proportion of patients with a monoclonal gammopathy is approximately 80 percent [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4,10\" class=\"abstract_t\">4,10</a>]. A review of 130 published cases of NXG found that the most frequent monoclonal immunoglobulin isotype was IgG (82 percent). IgA and IgM monoclonal gammopathies were much less common, occurring in only 3 and 2 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/11\" class=\"abstract_t\">11</a>]. Biclonal gammopathies were detected in a few patients. The light chain isotype kappa was present in 71 percent of patients, whereas the lambda isotype was present in 28 percent [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/11\" class=\"abstract_t\">11</a>]. Most patients had monoclonal gammopathy of undetermined significance (MGUS, 59 percent), followed by multiple myeloma (17 percent) [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Other hematologic disorders that have been reported in association with NXG include B-cell lymphoma, chronic lymphocytic leukemia [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/22\" class=\"abstract_t\">22</a>], Waldenstr&ouml;m macroglobulinemia [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/25\" class=\"abstract_t\">25</a>], non-Hodgkin's lymphoma [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/26\" class=\"abstract_t\">26</a>], and lymphoplasmacytic lymphoma [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/27\" class=\"abstract_t\">27</a>]. Hematologic disorders may precede or follow the development of cutaneous manifestations of NXG with intervals of up to several years or more between the two diagnoses [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6\" class=\"abstract_t\">6</a>]. A retrospective study of 17 patients seen at a tertiary care medical center found a mean time from the development of NXG to the development of a hematologic disorder of 2.4 years [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Other abnormalities have been reported in patients with NXG. Leukopenia may occur in one-third to one-half of patients [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/10,11\" class=\"abstract_t\">10,11</a>]. In addition, a C4 deficiency, elevated cholesterol and triglycerides [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/10,11,28\" class=\"abstract_t\">10,11,28</a>], cryoglobulinemia [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4,5,11,29\" class=\"abstract_t\">4,5,11,29</a>], and a C1-esterase inhibitor deficiency have been reported in patients with NXG [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5,28\" class=\"abstract_t\">5,28</a>]. The significance of the detection of <em>Borrelia</em> spirochetes with focus-floating microscopy in the skin biopsies of six patients with NXG is unclear [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H192580489\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Characteristic histologic findings of NXG include (<a href=\"image.htm?imageKey=DERM%2F103276%7EDERM%2F103278%7EDERM%2F103279\" class=\"graphic graphic_picture graphicRef103276 graphicRef103278 graphicRef103279 \">picture 3A-C</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Palisading histiocytic xanthogranulomas and bands of necrobiosis in the middle dermis extending into the panniculus [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4,31\" class=\"abstract_t\">4,31</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Touton-giant cells and characteristic bizarre-appearing, large foreign-body giant cells within xanthogranulomas</p><p/><p>Cholesterol clefts, lymphoid nodules (occasionally containing a germinal center), and plasma cells can also be seen. The plasma cells may be located perivascularly at the periphery of the lymphoid nodules or between dermal collagen fibers [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H1066258337\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of NXG is made based upon consideration of the clinical and histologic findings.</p><p class=\"headingAnchor\" id=\"H1066258344\"><span class=\"h2\">Clinical assessment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A full physical examination, including inspection of the skin, lymph nodes, and eyes, should be performed when NXG is suspected. Cutaneous findings that strongly suggest NXG are yellowish plaques with associated erythema in a periorbital location, particularly if central atrophy and telangiectasias are also present.</p><p>A complete review of systems should be obtained to evaluate for symptoms of extracutaneous involvement or underlying disease. In particular, the review of systems should include questions regarding ocular symptoms, unexplained weight loss, and lymphadenopathy.</p><p class=\"headingAnchor\" id=\"H1066258350\"><span class=\"h2\">Biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A skin biopsy from an involved area is recommended to confirm NXG and is usually diagnostic. A punch biopsy at least 4 mm in diameter is typically adequate. The biopsy should demonstrate palisading histiocytic xanthogranulomas, bands of necrobiosis in the dermis that extend into the subcutaneous fat, Touton-giant cells, and bizarre-appearing foreign-body giant cells (<a href=\"image.htm?imageKey=DERM%2F103276%7EDERM%2F103278%7EDERM%2F103279\" class=\"graphic graphic_picture graphicRef103276 graphicRef103278 graphicRef103279 \">picture 3A-C</a>). (See <a href=\"#H192580489\" class=\"local\">'Histopathology'</a> above.)</p><p class=\"headingAnchor\" id=\"H105668140\"><span class=\"h1\">FURTHER EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients diagnosed with NXG should be evaluated for an associated underlying disorder and systemic involvement. Initial laboratory tests to obtain in all patients include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete metabolic panel</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum and urine electrophoresis and immunofixation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum free light chain analysis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Computed tomography (CT) of the chest, abdomen, and pelvis</p><p/><p>Further testing should be based upon suspicion for specific underlying disorders based upon the review of systems and laboratory results. A bone marrow biopsy may be warranted if there is concern for myeloma or leukemia. (See <a href=\"topic.htm?path=diagnosis-of-monoclonal-gammopathy-of-undetermined-significance#H13\" class=\"medical medical_review\">&quot;Diagnosis of monoclonal gammopathy of undetermined significance&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=clinical-course-and-management-of-monoclonal-gammopathy-of-undetermined-significance\" class=\"medical medical_review\">&quot;Clinical course and management of monoclonal gammopathy of undetermined significance&quot;</a> and <a href=\"topic.htm?path=clinical-features-laboratory-manifestations-and-diagnosis-of-multiple-myeloma\" class=\"medical medical_review\">&quot;Clinical features, laboratory manifestations, and diagnosis of multiple myeloma&quot;</a>.)</p><p>Patients with periorbital NXG or ocular symptoms should be referred for ophthalmologic evaluation. CT or magnetic resonance imaging of the orbit may be needed to evaluate for ocular involvement if the patient has ocular complaints. Imaging of the body may be necessary if the physical examination, review of systems, or laboratory findings suggest systemic involvement.</p><p class=\"headingAnchor\" id=\"H1066258362\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical features of NXG can overlap with a variety of disorders. Plane xanthomas and necrobiosis lipoidica are often in the differential diagnosis.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Plane xanthomas </strong>&ndash; Plane xanthomas are cutaneous collections of lipid-laden macrophages that may occur independently or in association with hyperlipidemia, cholestasis, or monoclonal gammopathy. Plane xanthomas most commonly appear as yellow-orange, noninflamed plaques on sites such as the neck, trunk, flexural skin areas, or periorbital skin (<a href=\"image.htm?imageKey=DERM%2F102779\" class=\"graphic graphic_picture graphicRef102779 \">picture 4</a>). Xanthelasmas are plane xanthomas that occur on the eyelids (<a href=\"image.htm?imageKey=DERM%2F102780\" class=\"graphic graphic_picture graphicRef102780 \">picture 5</a>). The plaques of NXG tend to be larger and more erythematous, violaceous, indurated, or ulcerated than the homogenous yellowish plaques of plane xanthomas. (See <a href=\"topic.htm?path=cutaneous-xanthomas\" class=\"medical medical_review\">&quot;Cutaneous xanthomas&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Necrobiosis lipoidica </strong>&ndash; Necrobiosis lipoidica is a rare chronic granulomatous disease of the skin that often occurs in association with diabetes mellitus. Affected patients develop red-brown or violaceous papules or nodules that progress to form yellow-brown, atrophic, telangiectatic plaques that may ulcerate (<a href=\"image.htm?imageKey=DERM%2F76411\" class=\"graphic graphic_picture graphicRef76411 \">picture 6</a>). The anterior lower legs are the most common sites of involvement. Necrobiosis lipoidica may occur on the face and periorbitally [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/32\" class=\"abstract_t\">32</a>], although this occurs much less frequently than in NXG. Biopsies of necrobiosis lipoidica reveal a palisaded and interstitial granulomatous dermatitis with necrobiosis of collagen. In NXG, the necrobiosis and granulomatous infiltrate are much more extensive, and characteristic bizarre foreign-body giant cells and Touton-giant cells are present [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4\" class=\"abstract_t\">4</a>]. Furthermore, the lymphoid follicles often seen in NXG are not a common finding in necrobiosis lipoidica and cholesterol clefts are much more common in NXG [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4,6\" class=\"abstract_t\">4,6</a>]. (See <a href=\"topic.htm?path=necrobiosis-lipoidica#H312681761\" class=\"medical medical_review\">&quot;Necrobiosis lipoidica&quot;, section on 'Histopathology'</a> and <a href=\"topic.htm?path=necrobiosis-lipoidica\" class=\"medical medical_review\">&quot;Necrobiosis lipoidica&quot;</a>.)</p><p/><p>Other disorders that may present with clinical features that overlap with NXG are sarcoidosis, juvenile xanthogranulomas, granuloma annulare, xanthoma disseminatum, and panniculitides.</p><p class=\"headingAnchor\" id=\"H192577621\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of NXG is generally indicated given the chronic and progressive course and the potential for disfigurement, scarring, and ulceration. Successful treatment typically manifests as reductions in plaque size or prominence and healing of ulcerations. Complete resolution of cutaneous manifestations is rare.</p><p class=\"headingAnchor\" id=\"H1066258368\"><span class=\"h2\">Approach to treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of NXG is challenging and the best approach to treatment is unclear. Randomized controlled trials are lacking and data on treatment efficacy are limited to retrospective studies, small case series, and case reports. In addition, responses to the various treatments are inconsistent.</p><p>Given the lack of data on the comparative efficacy of treatments, the selection of an initial treatment can be influenced by patient-specific factors such as associated underlying diseases and disease severity, as well as concern for the risks and contraindications of particular treatments. In patients with NXG associated with an underlying malignancy, treatment should be directed at the underlying malignancy. For other patients, alkylating chemotherapeutic agents, such as <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> and <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a>, administered with or without systemic glucocorticoids, are most frequently cited in the literature as beneficial in the treatment of NXG and are considered appropriate first-line agents for this disease. For patients who cannot tolerate or fail to respond to an alkylating agent, limited data suggest that pulsed <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> and intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG) are reasonable second-line therapies. </p><p class=\"headingAnchor\" id=\"H192577848\"><span class=\"h2\">First-line therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The alkylating agents <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> and <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> may be used as first-line therapy for NXG in patients without an underlying malignancy. First-line therapy for patients with an associated malignancy is treatment of the malignancy. </p><p class=\"headingAnchor\" id=\"H27591627\"><span class=\"h3\">Alkylating agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retrospective studies and case reports suggest that <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> can be of benefit for NXG. In general, chlorambucil is better tolerated than <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> and is the preferred first-line treatment. </p><p>Examples of studies documenting the effects of <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> on NXG include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a review of 19 patients with NXG, 9 of 10 patients who were alive at the time of a follow-up study had received <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> (2 to 4 mg per day) for various periods. Of the 9 patients, 3 reported that chlorambucil induced near-complete clearing of cutaneous NXG, 4 reported some improvement, 1 reported stable disease, and 1 did not note an impact of chlorambucil on the disease [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4\" class=\"abstract_t\">4</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study of 17 patients with NXG, 4 received <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>. Of these, 2 patients had an excellent response, and 2 patients failed to respond [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study of 22 patients treated for NXG with multiple modalities, 3 patients treated with <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> monotherapy improved [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p>Multiple case reports also document responses of NXG to <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> as monotherapy or in combination with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/11,29,33-35\" class=\"abstract_t\">11,29,33-35</a>].</p><p><a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">Chlorambucil</a> is administered orally and is usually given for NXG at the relatively low dose of 2 to 4 mg per day. Potential adverse effects include gastrointestinal distress, hepatotoxicity, myelosuppression, central nervous system injury, pulmonary toxicity, amenorrhea, azoospermia, and secondary malignancy.</p><p><a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">Melphalan</a> is another alkylating agent that has been reported in retrospective studies and case reports to be effective for NXG when given as monotherapy or in combination with other agents [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4,6,28,36,37\" class=\"abstract_t\">4,6,28,36,37</a>]. Optimal dosing is unknown. Regimens associated with clinical improvement in case reports have included 10 mg of melphalan given with 60 mg of <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> for four consecutive days every three weeks for two cycles prior to skin grafting of NXG ulcers with additional cycles to maintain remission [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/37\" class=\"abstract_t\">37</a>] and 10 mg (0.15 <span class=\"nowrap\">mg/kg)</span> of melphalan given with <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a> for five consecutive days every four weeks for three cycles with additional cycles as needed [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/28\" class=\"abstract_t\">28</a>]. Melphalan failures are also documented [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5,34,38\" class=\"abstract_t\">5,34,38</a>]. Potential adverse effects of melphalan are gastrointestinal distress, myelosuppression, secondary malignancy, and hypersensitivity.</p><p>Oral <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> (1 <span class=\"nowrap\">mg/kg</span> per day) is an acceptable alternative alkylating agent based upon clinical experience. The duration of treatment is typically six months. Treatment beyond one year is not advised due to the risk of permanent myelosuppression and secondary myelodysplasia. Case reports also describe successful use of cyclophosphamide and <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> pulsed therapy for NXG [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/39,40\" class=\"abstract_t\">39,40</a>]. </p><p>There are reports of improvement in the cutaneous manifestations of NXG but not the gammopathy [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/28,41\" class=\"abstract_t\">28,41</a>], and vice-versa [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/38\" class=\"abstract_t\">38</a>], during treatment with alkylating agents.</p><p class=\"headingAnchor\" id=\"H192577886\"><span class=\"h2\">Second-line therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with an underlying malignancy, treatment should be directed based upon treatment protocols for that malignancy. For patients with NXG and no underlying malignancy, a variety of second-line therapies have been examined. Several reports document efficacy of systemic glucocorticoids and IVIG for NXG, suggesting that these treatments may be reasonable second-line therapies. Choosing between the two approaches is largely based upon consideration of toxicity and reimbursement (particularly for IVIG). &#160;</p><p class=\"headingAnchor\" id=\"H105668011\"><span class=\"h3\">Systemic glucocorticoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment with pulsed <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> (32 mg for days 1 to 3, 16 mg on day 4, 8 mg on day 5, 4 mg on days 6 and 7) has been associated with improvement in NXG in individual patients [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6,42,43\" class=\"abstract_t\">6,42,43</a>]. In addition, treatment with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> was associated with healing of NXG ulcers in a patient given 60 mg of prednisone per day [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/13\" class=\"abstract_t\">13</a>]. Prednisone also was associated with improvement of NXG in 3 of 11 patients in a retrospective study [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5\" class=\"abstract_t\">5</a>]. Side effects of systemic glucocorticoids are reviewed in detail separately. (See <a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">&quot;Major side effects of systemic glucocorticoids&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H105668107\"><span class=\"h3\">Intravenous immune globulin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several case reports suggest that intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG) can be beneficial for NXG [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/44-47\" class=\"abstract_t\">44-47</a>]. IVIG is typically administered in a cyclical manner with three- to four-week intervals between treatments. Optimal dosing for NXG is unknown. The cost of IVIG may be a limiting factor. Side effects of IVIG are reviewed in detail separately. (See <a href=\"topic.htm?path=intravenous-immune-globulin-adverse-effects\" class=\"medical medical_review\">&quot;Intravenous immune globulin: Adverse effects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H192577879\"><span class=\"h2\">Other therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A few reports document benefit of other therapeutic interventions for NXG in individual patients. These include <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6\" class=\"abstract_t\">6</a>], autologous stem cell transplantation [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6,48\" class=\"abstract_t\">6,48</a>], <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">lenalidomide</a> [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/49\" class=\"abstract_t\">49</a>], <a href=\"topic.htm?path=interferon-alfa-2b-drug-information\" class=\"drug drug_general\">interferon alfa-2b</a> [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/50\" class=\"abstract_t\">50</a>], interferon alfa-2a [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/51\" class=\"abstract_t\">51</a>], plasmapheresis [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/52\" class=\"abstract_t\">52</a>], <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/53\" class=\"abstract_t\">53</a>], psoralen plus ultraviolet A [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/54\" class=\"abstract_t\">54</a>], <a href=\"topic.htm?path=mechlorethamine-nitrogen-mustard-topical-gel-drug-information\" class=\"drug drug_general\">topical nitrogen mustard</a> [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/55\" class=\"abstract_t\">55</a>], and topical glucosides of peony [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/56\" class=\"abstract_t\">56</a>]. In addition, a patient with small lymphocytic lymphoma, Sj&ouml;gren syndrome, and periocular NXG treated with <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a>, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, and <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> experienced resolution of NXG and sicca symptoms [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/57\" class=\"abstract_t\">57</a>]. Rituximab monotherapy demonstrated efficacy in one patient with bilateral orbital NXG and no underlying paraproteinemia [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/58\" class=\"abstract_t\">58</a>]. Poor results from treatment with <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, and systemic nitrogen mustard have occurred in individual patients [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Selection amongst the above agents is largely based upon consideration of toxicity and comorbidities. <a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">Lenalidomide</a> (favored over <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> due to toxicity profile) is a reasonable option in NXG associated with monoclonal gammopathy, even if there is no evidence of overt multiple myeloma. Interferon is a reasonable option if a monoclonal gammopathy is not present or if there is a lack of response to lenalidomide given the activity of interferon in other histiocyte disorders and scattered case reports documenting efficacy in NXG. <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">Dapsone</a> and plasmapheresis are reserved for more refractory cases. </p><p>Procedural therapies have been employed for the treatment of NXG. Intralesional steroids have very little toxicity and are a reasonable approach for patients with a small number of easily accessible lesions. Both efficacy and inefficacy of intralesional corticosteroid therapy have been reported [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5,6,59\" class=\"abstract_t\">5,6,59</a>]. Surgical excision of NXG has been linked to improvement in NXG when used as monotherapy [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/60,61\" class=\"abstract_t\">60,61</a>], following radiation [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6\" class=\"abstract_t\">6</a>], or preceding <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> therapy [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/62\" class=\"abstract_t\">62</a>]. However, the use of surgical excision for NXG is controversial because of concern for high risk of recurrence. Excision is generally not recommended unless the disease is exerting a mass effect that requires immediate debulking (particularly if prior systemic or local therapy has not been effective) [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/3,5\" class=\"abstract_t\">3,5</a>].</p><p>Radiation has been used with success in some cases [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5,6,63\" class=\"abstract_t\">5,6,63</a>]. In addition, case reports document improvement in NXG after treatment with a carbon dioxide laser [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/27\" class=\"abstract_t\">27</a>] and improvement in facial hyperpigmentation secondary to NXG after treatment with a Q-switched 650 nm wavelength laser [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/64\" class=\"abstract_t\">64</a>].</p><p class=\"headingAnchor\" id=\"H1066258392\"><span class=\"h1\">PROGNOSIS AND FOLLOW-UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with NXG are at an increased risk for hematologic disorders. In a retrospective study of 48 patients with NXG, 13 percent developed a malignancy, including leukemia and lymphoma [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4\" class=\"abstract_t\">4</a>].</p><p>There are no standard recommendations regarding monitoring of these patients. Given the high association with a monoclonal gammopathy and the low but existing risk for progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma, Waldenstr&ouml;m macroglobulinemia, amyloidosis, or a malignant lymphoproliferative disorder [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/65\" class=\"abstract_t\">65</a>], patients need to have regular follow-up, including a complete blood count, complete metabolic panel, and immunofixation electrophoresis, at least every six months. The course of the paraproteinemia often does not parallel the course of skin disease [<a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5\" class=\"abstract_t\">5</a>]; thus, flaring of skin disease is not a reliable indicator of worsening proteinemia.</p><p>No characteristics have been identified to predict which patients with NXG will develop a malignancy. Recommendations for monitoring patients with MGUS for progression to a malignant plasma cell dyscrasia or lymphoproliferative disorder are reviewed separately. (See <a href=\"topic.htm?path=clinical-course-and-management-of-monoclonal-gammopathy-of-undetermined-significance\" class=\"medical medical_review\">&quot;Clinical course and management of monoclonal gammopathy of undetermined significance&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1066258398\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Necrobiotic xanthogranuloma is a rare non-Langerhans histiocytosis that often occurs in association with monoclonal gammopathy. NXG typically occurs in adults. The average age of onset is in the sixth decade. The pathogenesis is unclear. (See <a href=\"#H1066258294\" class=\"local\">'Epidemiology'</a> above and <a href=\"#H1066258300\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NXG usually begins as yellow-orange, red-brown, or violaceous papules or nodules that evolve into infiltrated plaques. The plaques may exhibit central atrophy or telangiectasias. Ulceration and scarring are common. Extracutaneous involvement may occur in the respiratory tract, heart, or other tissues. (See <a href=\"#H1066258306\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients with NXG have a monoclonal gammopathy. Other hematologic disorders, including malignancies, may also occur in patients with NXG. Hematologic disorders may precede or follow the development of NXG. (See <a href=\"#H1066258331\" class=\"local\">'Associated disorders'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of NXG is made by the recognition of consistent clinical and histologic findings. A skin biopsy characteristically demonstrates palisading histiocytic xanthogranulomas, bands of necrobiosis that extend to the subcutaneous fat, Touton-giant cells, and large, bizarre-appearing foreign-body giant cells. (See <a href=\"#H192580489\" class=\"local\">'Histopathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The evaluation of patients with NXG should include a review of systems and laboratory studies to look for evidence of systemic involvement and underlying disease. Follow-up for the development of hematologic disorders is necessary for patients with NXG. (See <a href=\"#H1066258337\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H105668140\" class=\"local\">'Further evaluation'</a> above and <a href=\"#H1066258392\" class=\"local\">'Prognosis and follow-up'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Data on the treatment of NXG are limited, preventing definitive guidelines for the best approach to treatment. In patients with NXG associated with an underlying malignancy, treatment should be directed at the underlying malignancy. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with NXG that is <strong>not</strong> associated with an underlying malignancy, we suggest treatment with <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a> or <a href=\"topic.htm?path=melphalan-drug-information\" class=\"drug drug_general\">melphalan</a> as first-line treatment (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We prefer chlorambucil because the drug is better tolerated than melphalan. <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">Cyclophosphamide</a> is an alternative alkylating agent. Patients who cannot receive an alkylating agent or fail to respond may benefit from systemic glucocorticoids, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a>, or other treatments. (See <a href=\"#H192577621\" class=\"local\">'Treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/1\" class=\"nounderline abstract_t\">Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol 1980; 3:257.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/2\" class=\"nounderline abstract_t\">Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma. Australas J Dermatol 1980; 21:85.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/3\" class=\"nounderline abstract_t\">Ugurlu S, Bartley GB, Gibson LE. Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am J Ophthalmol 2000; 129:651.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/4\" class=\"nounderline abstract_t\">Mehregan DA, Winkelmann RK. Necrobiotic xanthogranuloma. Arch Dermatol 1992; 128:94.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/5\" class=\"nounderline abstract_t\">Finan MC, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. A review of 22 cases. Medicine (Baltimore) 1986; 65:376.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/6\" class=\"nounderline abstract_t\">Wood AJ, Wagner MV, Abbott JJ, Gibson LE. Necrobiotic xanthogranuloma: a review of 17 cases with emphasis on clinical and pathologic correlation. Arch Dermatol 2009; 145:279.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/7\" class=\"nounderline abstract_t\">Bullock JD, Bartley GB, Campbell RJ, et al. Necrobiotic xanthogranuloma with paraproteinemia. Case report and a pathogenetic theory. Ophthalmology 1986; 93:1233.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/8\" class=\"nounderline abstract_t\">Matsuura F, Yamashita S, Hirano K, et al. Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia--a possible pathogenesis of necrobiotic xanthogranuloma. Atherosclerosis 1999; 142:355.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/9\" class=\"nounderline abstract_t\">Szalat R, Pirault J, Fermand JP, et al. Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy. J Intern Med 2014; 276:269.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/10\" class=\"nounderline abstract_t\">Spicknall KE, Mehregan DA. Necrobiotic xanthogranuloma. Int J Dermatol 2009; 48:1.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/11\" class=\"nounderline abstract_t\">Szalat R, Arnulf B, Karlin L, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood 2011; 118:3777.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/12\" class=\"nounderline abstract_t\">Ghiasi N, Alavi A, Coutts PM, et al. Necrobiotic xanthogranuloma as an unusual cause of refractive chronic bilateral leg ulceration. Int J Low Extrem Wounds 2012; 11:293.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/13\" class=\"nounderline abstract_t\">Sabet LM, Wexler D, Salama S, Gan BS. An unusual cause of refractive chronic bilateral leg ulceration. J Cutan Med Surg 2004; 8:432.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/14\" class=\"nounderline abstract_t\">Khan M, Ahmed I, Carr R. An unusual subcutaneous lump. Clin Exp Dermatol 2012; 37:808.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/15\" class=\"nounderline abstract_t\">Chang SE, Lee WS, Lee MW, et al. A case of necrobiotic xanthogranuloma without paraproteinemia presenting as a solitary tumor on the thigh. Int J Dermatol 2003; 42:470.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/16\" class=\"nounderline abstract_t\">Stork J, Kodetov&aacute; D, Vosm&iacute;k F, Krejca M. Necrobiotic xanthogranuloma presenting as a solitary tumor. Am J Dermatopathol 2000; 22:453.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/17\" class=\"nounderline abstract_t\">Bain EE 3rd, Meehan SA, Hale EK. Solitary necrobiotic xanthogranuloma of an upper extremity in association with multiple myeloma. J Drugs Dermatol 2014; 13:598.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/18\" class=\"nounderline abstract_t\">DeLuca IJ, Grossman ME. Vulvar necrobiotic xanthogranuloma. J Am Acad Dermatol 2014; 71:e247.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/19\" class=\"nounderline abstract_t\">Koch PS, Goerdt S, G&eacute;raud C. Erythematous papules, plaques, and nodular lesions on the trunk and within preexisting scars. JAMA Dermatol 2013; 149:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/20\" class=\"nounderline abstract_t\">Rayner SA, Duncombe AS, Keefe M, et al. Necrobiotic xanthogranuloma occurring in an eyelid scar. Orbit 2008; 27:191.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/21\" class=\"nounderline abstract_t\">G&uuml;n D, Demir&ccedil;ay Z, Demirkesen C. Necrobiotic xanthogranuloma in a burn scar. Int J Dermatol 2004; 43:293.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/22\" class=\"nounderline abstract_t\">Mohsenin A, Sinard J, Huang JJ. Necrobiotic xanthogranuloma and chronic lymphocytic leukemia of the conjunctiva masquerading as scleritis and uveitis. Clin Ophthalmol 2012; 6:2045.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/23\" class=\"nounderline abstract_t\">Peyman A, Walsh N, Green P, et al. Necrobiotic xanthogranuloma associated with necrotizing scleritis. Am J Dermatopathol 2012; 34:644.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/24\" class=\"nounderline abstract_t\">Seastrom S, Bookout A, Hogan DJ. Necrobiotic xanthogranuloma without a monoclonal gammopathy. Cutis 2014; 94:293.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/25\" class=\"nounderline abstract_t\">Balagula Y, Straus DJ, Pulitzer MP, Lacouture ME. Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenstr&ouml;m macroglobulinemia. J Clin Oncol 2011; 29:e305.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/26\" class=\"nounderline abstract_t\">Oumeish OY, Oumeish I, Tarawneh M, et al. Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol 2006; 45:306.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/27\" class=\"nounderline abstract_t\">Vieira V, Del Pozo J, Mart&iacute;nez W, et al. Necrobiotic xanthogranuloma associated with lymphoplasmacytic lymphoma. Palliative treatment with carbon dioxide laser. Eur J Dermatol 2005; 15:182.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/28\" class=\"nounderline abstract_t\">Macfarlane AW, Verbov JL. Necrobiotic xanthogranuloma with paraproteinaemia. Br J Dermatol 1985; 113:339.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/29\" class=\"nounderline abstract_t\">Machado S, Alves R, Lima M, et al. Cutaneous necrobiotic xanthogranuloma (NXG)--successfully treated with low dose chlorambucil. Eur J Dermatol 2001; 11:458.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/30\" class=\"nounderline abstract_t\">Zelger B, Eisendle K, Mensing C, Zelger B. Detection of spirochetal micro-organisms by focus-floating microscopy in necrobiotic xanthogranuloma. J Am Acad Dermatol 2007; 57:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/31\" class=\"nounderline abstract_t\">Finan MC, Winkelmann RK. Histopathology of necrobiotic xanthogranuloma with paraproteinemia. J Cutan Pathol 1987; 14:92.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/32\" class=\"nounderline abstract_t\">V&eacute;lez A, Mart&iacute;n-de-Hijas C, del-R&iacute;o E, Ambrojo P. Ulcerated plaque of the face. Atypical necrobiosis lipoidica. Arch Dermatol 1994; 130:1433, 1436.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/33\" class=\"nounderline abstract_t\">Winkelmann RK, Litzow MR, Umbert IJ, Lie JT. Giant cell granulomatous pulmonary and myocardial lesions in necrobiotic xanthogranuloma with paraproteinemia. Mayo Clin Proc 1997; 72:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/34\" class=\"nounderline abstract_t\">Wells J, Gillespie R, Zardawi I. Case of recalcitrant necrobiotic xanthogranuloma. Australas J Dermatol 2004; 45:213.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/35\" class=\"nounderline abstract_t\">Ryan E, Warren LJ, Szabo F. Necrobiotic xanthogranuloma: response to chlorambucil. Australas J Dermatol 2012; 53:e23.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/36\" class=\"nounderline abstract_t\">Criado PR, Vasconcellos C, Pegas JR, et al. Necrobiotic xanthogranuloma with lambda paraproteinemia: case report of successful treatment with melphalan and prednisone. J Dermatolog Treat 2002; 13:87.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/37\" class=\"nounderline abstract_t\">Saeki H, Tomita M, Kai H, et al. Necrobiotic xanthogranuloma with paraproteinemia successfully treated with melphalan, prednisolone and skin graft. J Dermatol 2007; 34:795.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/38\" class=\"nounderline abstract_t\">Ziemer M, Wedding U, Sander CS, Elsner P. Necrobiotic xanthogranuloma-rapid progression under treatment with melphalan. Eur J Dermatol 2005; 15:363.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/39\" class=\"nounderline abstract_t\">Meyer S, Szeimies RM, Landthaler M, Hohenleutner S. Cyclophosphamide-dexamethasone pulsed therapy for treatment of recalcitrant necrobiotic xanthogranuloma with paraproteinemia and ocular involvement. Br J Dermatol 2005; 153:443.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/40\" class=\"nounderline abstract_t\">Khan IJ, Azam NA, Sullivan SC, et al. Necrobiotic xanthogranuloma successfully treated with a combination of dexamethasone and oral cyclophosphamide. Can J Ophthalmol 2009; 44:335.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/41\" class=\"nounderline abstract_t\">Torabian SZ, Fazel N, Knuttle R. Necrobiotic xanthogranuloma treated with chlorambucil. Dermatol Online J 2006; 12:11.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/42\" class=\"nounderline abstract_t\">Plotnick H, Taniguchi Y, Hashimoto K, et al. Periorbital necrobiotic xanthogranuloma and stage I multiple myeloma. Ultrastructure and response to pulsed dexamethasone documented by magnetic resonance imaging. J Am Acad Dermatol 1991; 25:373.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/43\" class=\"nounderline abstract_t\">Chave TA, Chowdhury MM, Holt PJ. Recalcitrant necrobiotic xanthogranuloma responding to pulsed high-dose oral dexamethasone plus maintenance therapy with oral prednisolone. Br J Dermatol 2001; 144:158.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/44\" class=\"nounderline abstract_t\">Hallermann C, Tittelbach J, Norgauer J, Ziemer M. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. Arch Dermatol 2010; 146:957.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/45\" class=\"nounderline abstract_t\">Rubinstein A, Wolf DJ, Granstein RD. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. J Cutan Med Surg 2013; 17:347.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/46\" class=\"nounderline abstract_t\">Liszewski W, Wisniewski JD, Safah H, Boh EE. Treatment of refractory necrobiotic xanthogranulomas with extracorporeal photopheresis and intravenous immunoglobulin. Dermatol Ther 2014; 27:268.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/47\" class=\"nounderline abstract_t\">Pedrosa AF, Ferreira O, Calistru A, et al. Necrobiotic xanthogranuloma with giant cell hepatitis, successfully treated with intravenous immunoglobulins. Dermatol Ther 2015; 28:68.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/48\" class=\"nounderline abstract_t\">Goede JS, Misselwitz B, Taverna C, et al. Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation. Ann Hematol 2007; 86:303.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/49\" class=\"nounderline abstract_t\">Silapunt S, Chon SY. Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide. J Drugs Dermatol 2010; 9:273.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/50\" class=\"nounderline abstract_t\">Venencie PY, Le Bras P, Toan ND, et al. Recombinant interferon alfa-2b treatment of necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol 1995; 32:666.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/51\" class=\"nounderline abstract_t\">Georgiou S, Monastirli A, Kapranos N, et al. Interferon alpha-2a monotherapy for necrobiotic xanthogranuloma. Acta Derm Venereol 1999; 79:484.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/52\" class=\"nounderline abstract_t\">Finelli LG, Ratz JL. Plasmapheresis, a treatment modality for necrobiotic xanthogranuloma. J Am Acad Dermatol 1987; 17:351.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/53\" class=\"nounderline abstract_t\">Wei YH, Cheng JJ, Wu YH, et al. Necrobiotic xanthogranuloma: response to dapsone. Dermatol Ther 2015; 28:7.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/54\" class=\"nounderline abstract_t\">Al-Niaimi FA, Dawn G, Cox NH. Necrobiotic xanthogranuloma without paraproteinaemia: marked improvement with psoralen ultraviolet A treatment. Clin Exp Dermatol 2010; 35:275.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/55\" class=\"nounderline abstract_t\">Rodriguez O, Meyers C, Weiss BM, et al. Necrobiotic Xanthogranuloma Treated With Topical Nitrogen Mustard (Mechlorethamine). JAMA Dermatol 2016; 152:589.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/56\" class=\"nounderline abstract_t\">Li S, Chen AJ, Fang S, Li H. Successful treatment of necrobiotic xanthogranuloma with total glucosides of paeony. Dermatol Ther 2014; 27:304.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/57\" class=\"nounderline abstract_t\">Naghashpour M, Setoodeh R, Moscinski L, et al. Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sj&ouml;gren syndrome. Am J Dermatopathol 2011; 33:855.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/58\" class=\"nounderline abstract_t\">Sagiv O, Thakar SD, Morrell G, et al. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. Ophthal Plast Reconstr Surg 2018; 34:e24.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/59\" class=\"nounderline abstract_t\">Elner VM, Mintz R, Demirci H, Hassan AS. Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Ophthal Plast Reconstr Surg 2006; 22:36.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/60\" class=\"nounderline abstract_t\">Chandra S, Finklestein E, Gill D. Necrobiotic xanthogranuloma occurring within linear morphoea. Australas J Dermatol 2002; 43:52.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/61\" class=\"nounderline abstract_t\">Schaudig U, Al-Samir K. Upper and lower eyelid reconstruction for severe disfiguring necrobiotic xanthogranuloma. Orbit 2004; 23:65.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/62\" class=\"nounderline abstract_t\">Mart&iacute;nez Fern&aacute;ndez M, Rodr&iacute;guez Prieto MA, Ruiz Gonz&aacute;lez I, et al. Necrobiotic xanthogranuloma associated with myeloma. J Eur Acad Dermatol Venereol 2004; 18:328.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/63\" class=\"nounderline abstract_t\">Char DH, LeBoit PE, Ljung BM, Wara W. Radiation therapy for ocular necrobiotic xanthogranuloma. Arch Ophthalmol 1987; 105:174.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/64\" class=\"nounderline abstract_t\">Hamilton HK, Dover JS, Arndt KA. Successful treatment of disfiguring hemosiderin-containing hyperpigmentation with the Q-switched 650-nm wavelength laser. JAMA Dermatol 2014; 150:1221.</a></li><li><a href=\"https://www.uptodate.com/contents/necrobiotic-xanthogranuloma/abstract/65\" class=\"nounderline abstract_t\">Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79:859.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 89275 Version 6.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1066258398\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1066258288\" id=\"outline-link-H1066258288\">INTRODUCTION</a></li><li><a href=\"#H88245963\" id=\"outline-link-H88245963\">HISTORY</a></li><li><a href=\"#H1066258294\" id=\"outline-link-H1066258294\">EPIDEMIOLOGY</a></li><li><a href=\"#H1066258300\" id=\"outline-link-H1066258300\">PATHOGENESIS</a></li><li><a href=\"#H1066258306\" id=\"outline-link-H1066258306\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H1066258313\" id=\"outline-link-H1066258313\">Cutaneous</a></li><li><a href=\"#H1066258319\" id=\"outline-link-H1066258319\">Extracutaneous</a><ul><li><a href=\"#H356857559\" id=\"outline-link-H356857559\">- Ocular involvement</a></li><li><a href=\"#H356857632\" id=\"outline-link-H356857632\">- Other sites</a></li></ul></li></ul></li><li><a href=\"#H1066258331\" id=\"outline-link-H1066258331\">ASSOCIATED DISORDERS</a></li><li><a href=\"#H192580489\" id=\"outline-link-H192580489\">HISTOPATHOLOGY</a></li><li><a href=\"#H1066258337\" id=\"outline-link-H1066258337\">DIAGNOSIS</a><ul><li><a href=\"#H1066258344\" id=\"outline-link-H1066258344\">Clinical assessment</a></li><li><a href=\"#H1066258350\" id=\"outline-link-H1066258350\">Biopsy</a></li></ul></li><li><a href=\"#H105668140\" id=\"outline-link-H105668140\">FURTHER EVALUATION</a></li><li><a href=\"#H1066258362\" id=\"outline-link-H1066258362\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H192577621\" id=\"outline-link-H192577621\">TREATMENT</a><ul><li><a href=\"#H1066258368\" id=\"outline-link-H1066258368\">Approach to treatment</a></li><li><a href=\"#H192577848\" id=\"outline-link-H192577848\">First-line therapy</a><ul><li><a href=\"#H27591627\" id=\"outline-link-H27591627\">- Alkylating agents</a></li></ul></li><li><a href=\"#H192577886\" id=\"outline-link-H192577886\">Second-line therapy</a><ul><li><a href=\"#H105668011\" id=\"outline-link-H105668011\">- Systemic glucocorticoids</a></li><li><a href=\"#H105668107\" id=\"outline-link-H105668107\">- Intravenous immune globulin</a></li></ul></li><li><a href=\"#H192577879\" id=\"outline-link-H192577879\">Other therapies</a></li></ul></li><li><a href=\"#H1066258392\" id=\"outline-link-H1066258392\">PROGNOSIS AND FOLLOW-UP</a></li><li><a href=\"#H1066258398\" id=\"outline-link-H1066258398\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/89275|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/102781\" class=\"graphic graphic_picture\">- Periorbital necrobiotic xanthogranuloma</a></li><li><a href=\"image.htm?imageKey=DERM/102782\" class=\"graphic graphic_picture\">- Necrobiotic xanthogranuloma</a></li><li><a href=\"image.htm?imageKey=DERM/102783\" class=\"graphic graphic_picture\">- Ulcerated necrobiotic xanthogranuloma</a></li><li><a href=\"image.htm?imageKey=DERM/103276\" class=\"graphic graphic_picture\">- Necrobiotic xanthogranuloma cholesterol clefts</a></li><li><a href=\"image.htm?imageKey=DERM/103278\" class=\"graphic graphic_picture\">- Necrobiotic xanthogranuloma necrobiosis and giant cells</a></li><li><a href=\"image.htm?imageKey=DERM/103279\" class=\"graphic graphic_picture\">- Necrobiotic xanthogranuloma cholesterol clefts and giant cells</a></li><li><a href=\"image.htm?imageKey=DERM/102779\" class=\"graphic graphic_picture\">- Plane xanthoma</a></li><li><a href=\"image.htm?imageKey=DERM/102780\" class=\"graphic graphic_picture\">- Xanthelasma on eyelid</a></li><li><a href=\"image.htm?imageKey=DERM/76411\" class=\"graphic graphic_picture\">- Necrobiosis lipoidica 4</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-course-and-management-of-monoclonal-gammopathy-of-undetermined-significance\" class=\"medical medical_review\">Clinical course and management of monoclonal gammopathy of undetermined significance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-laboratory-manifestations-and-diagnosis-of-multiple-myeloma\" class=\"medical medical_review\">Clinical features, laboratory manifestations, and diagnosis of multiple myeloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-xanthomas\" class=\"medical medical_review\">Cutaneous xanthomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-monoclonal-gammopathy-of-undetermined-significance\" class=\"medical medical_review\">Diagnosis of monoclonal gammopathy of undetermined significance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intravenous-immune-globulin-adverse-effects\" class=\"medical medical_review\">Intravenous immune globulin: Adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">Major side effects of systemic glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=necrobiosis-lipoidica\" class=\"medical medical_review\">Necrobiosis lipoidica</a></li></ul></div></div>","javascript":null}